Home / Business and Economy / Pfizer's Weight Loss Drug Now in China Market
Pfizer's Weight Loss Drug Now in China Market
22 Apr
Summary
- Pfizer's Xianweiying, a GLP-1 weight management treatment, is now available for pre-order in China.
- The treatment is priced at 489 yuan ($72) for a 1.2 ml injector pen.
- This launch intensifies competition in China's rapidly growing weight-loss drug market.
Pfizer's GLP-1 weight management treatment, known as Xianweiying or ecnoglutide, has become available for pre-order in China. A Reuters check on a local e-commerce platform revealed that a 1.2 ml injector pen is listed for 489 yuan ($72), with shipping to commence on April 27. This development signifies Pfizer's increased presence in China's lucrative weight-loss drug market.
The introduction of Xianweiying escalates competition among pharmaceutical giants in this sector. Rivals such as Novo Nordisk, Eli Lilly, and Innovent Biologics already offer GLP-1 receptor agonist drugs in the market. Sales for Novo Nordisk's Wegovy and Innovent's Xinermei reached 260 million yuan ($38 million) and 416 million yuan ($61 million) respectively in 2025, according to Jefferies.
Pfizer secured the mainland China commercialization rights for Xianweiying from Sciwind in February. The company has also recently expanded its portfolio by acquiring obesity drug developer Metsera and another experimental GLP-1 drug. Ecnoglutide also holds approval in China for the treatment of Type 2 diabetes.
